Regeneron Pharmaceuticals, Inc. (REGN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Regeneron Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Regeneron Pharmaceuticals, Inc. (REGN) has returned 0.22% so far this year and 22.49% over the past 12 months. Over the last ten years, REGN has returned 6.74% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Apr 2, 1991, REGN's average daily return is +0.12%, while the average monthly return is +2.82%. At this rate, your investment would double in approximately 2.1 years.

Historically, 50% of months were positive and 50% were negative. The best month was Feb 2000 with a return of +359.0%, while the worst month was Mar 2003 at -59.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, REGN closed higher 47% of trading days. The best single day was Feb 23, 2000 with a return of +75.4%, while the worst single day was Mar 31, 2003 at -56.6%.

Regeneron Pharmaceuticals, Inc. has an annualized alpha of 21.59%, beta of 1.10, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since April 03, 1991.

• This stock captured 122.01% of S&P 500 Index gains and 110.15% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

REGN ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and compare them to a chosen benchmark (S&P 500 Index).

Regeneron Pharmaceuticals, Inc. provided a 0.46% dividend yield over the last twelve months, with an annual payout of $3.58 per share.

The table displays the monthly dividend distributions for Regeneron Pharmaceuticals, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Regeneron Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Regeneron Pharmaceuticals, Inc. was 91.81%, occurring on Apr 14, 2005. Recovery took 1520 trading sessions.

The current Regeneron Pharmaceuticals, Inc. drawdown is 35.27%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Regeneron Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Regeneron Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.